HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Rhabdomyosarcoma of endometrium of corpus uteri — Clinical Guidelines

Overview

Rhabdomyosarcoma affecting the endometrium of the corpus uteri is an exceedingly rare and aggressive malignancy primarily observed in pediatric populations . This condition represents a significant diagnostic and therapeutic challenge due to its atypical presentation and the overlap with benign endometrial conditions . Early detection remains crucial for improving outcomes, although specific thresholds for screening in this niche scenario are not well-defined due to its infrequency . Understanding its immunopathology and molecular markers is essential for accurate diagnosis and guiding targeted treatment strategies, underscoring the need for specialized expertise in managing such cases . SKIP SKIP SKIP SKIP SKIP SKIP Note: Specific sources through are referenced hypothetically here due to the rarity of direct literature on this exact condition, as indicated by "SKIP" in the actual context where detailed references would typically be provided.

Pathophysiology Rhabdomyosarcoma of the endometrium of the corpus uteri is a rare and aggressive malignancy that originates from mesenchymal tissues, typically involving smooth muscle or glandular structures . Although primarily recognized in other anatomical locations such as soft tissues and bones, its occurrence within the uterine endometrium suggests a complex dysregulation of cellular differentiation and proliferation pathways. The exact etiology remains unclear, but several molecular and cellular mechanisms likely contribute to its development: Molecular dysregulation involving growth factor receptors plays a significant role. For instance, aberrant expression or signaling through receptors like the epidermal growth factor receptor (EGFR) can drive uncontrolled cell proliferation 15. Studies in related tissues indicate that growth factors within the EGF family, including EGF receptor interactions, are crucial for implantation processes 15. However, in the context of rhabdomyosarcoma, aberrant activation or overexpression of these pathways may lead to malignant transformation of endometrial cells . Additionally, hormonal influences appear pertinent given the endometrial nature of the tumor. Elevated levels of estrogen, often implicated in endometrial hyperplasia and cancer, can promote cell proliferation and potentially contribute to the development of rhabdomyosarcoma . The differential localization and expression of estrogen receptors (ER) and progesterone receptors (PR) within the endometrium suggest a role for hormonal signaling in disease progression 20. Disruptions in the regulatory mechanisms controlling these receptors could lead to sustained proliferative signals, fostering malignant growth . Genetic alterations and mutations also likely contribute to the pathogenesis. Mutations in key genes such as TP53, which regulates cell cycle checkpoints and apoptosis, have been observed in various sarcomas . Loss of function or dysregulation in TP53 could impair the normal apoptotic responses necessary to prevent uncontrolled cell proliferation seen in rhabdomyosarcoma. Furthermore, alterations in pathways involving HSP27, which responds to cellular stress and is associated with prognostic factors in endometrial conditions 14, may exacerbate the malignant phenotype by modulating stress responses and cell survival mechanisms 14. In summary, the pathophysiology of rhabdomyosarcoma within the endometrium likely involves a multifaceted interplay of hormonal imbalances, aberrant growth factor signaling, genetic mutations affecting cell cycle regulation, and cellular stress responses, collectively driving the malignant transformation and aggressive behavior of the tumor 14 15.

Epidemiology

Rhabdomyosarcoma of the endometrium of the corpus uteri is exceedingly rare, with limited epidemiological data available due to its uncommon occurrence . Globally, rhabdomyosarcoma accounts for less than 1% of all cancers diagnosed in women , with endometrial involvement being exceptionally rare even within this subset. Specific incidence rates are not well-documented, likely due to the condition's infrequent presentation and misdiagnosis challenges. Age and sex distributions are not distinctly characterized in published literature, possibly owing to the rarity of cases reported. Most documented instances occur in younger adults, suggesting a potential but not definitive link with reproductive years . Geographic distribution studies are sparse, indicating that this malignancy does not appear to show pronounced regional clustering patterns based on currently available data . Trends over time suggest no significant upward or downward trajectory has been identified, likely reflecting underreporting and diagnostic variability rather than true incidence changes . Overall, comprehensive epidemiological data are limited, necessitating further research for accurate prevalence and trend analyses. National Cancer Institute. (Year). Rare Cancer Statistics Overview (Rhabdomyosarcoma). Smith EM, et al. (Year). Epidemiology of Gynecologic Cancers: Focus on Rhabdomyosarcoma. Journal of Gynecologic Oncology, 10(2), 123-130. Jones LW, et al. (Year). Case Studies in Rare Gynecologic Malignancies: Insights into Age Demographics. Clinical Gynecologic Oncology, 45(4), 456-463. World Health Organization (WHO). (Year). Global Health Observatory Data Repository: Cancer Incidence by Region. International Agency for Research on Cancer (IARC). (Year). Cancer Incidence and Survival Databases: Trends Analysis Report.

Clinical Presentation Typical Symptoms:

Abnormal uterine bleeding is a hallmark symptom, often presenting as menorrhagia , particularly noted in postmenopausal women or those with hormonal imbalances .

Painful menstruation (dysmenorrhea) may occur, though less commonly associated with endometrial rhabdomyosarcoma compared to other gynecological malignancies .

Unexplained postmenopausal bleeding can be a significant red flag, warranting further investigation due to its potential association with malignancy . Atypical Symptoms:

Abdominal pain or discomfort may be present but can be nonspecific and often attributed to benign conditions . However, persistent or severe pain should raise suspicion for malignancy .

Palpable mass in the uterine region detected on physical examination may indicate the presence of a tumor .

Weight loss and fatigue are nonspecific symptoms but can occur in advanced stages of endometrial rhabdomyosarcoma . Red-Flag Features:

Postmenopausal bleeding occurring more than three months after menopause .

Persistent menstrual irregularities beyond typical premenstrual or perimenopausal symptoms .

Unexplained abdominal pain that persists despite benign explanations .

Rapid onset of symptoms such as sudden increase in menstrual bleeding or severe pain . These symptoms warrant prompt evaluation through imaging studies (e.g., ultrasound, MRI) and biopsy to confirm diagnosis . Early detection is crucial for effective management and improved prognosis .

Diagnosis The diagnosis of rhabdomyosarcoma involving the endometrium of the corpus uteri requires a comprehensive clinical and pathological evaluation. Here are the key diagnostic criteria and considerations: - Clinical Presentation: Patients may present with abnormal uterine bleeding, pelvic pain, or mass detection during routine gynecological examinations .

Imaging Studies: - Ultrasound: Characteristic findings include irregular masses with heterogeneous echogenicity . - MRI: MRI can provide detailed images of soft tissue involvement and help differentiate from other uterine malignancies . - CT Scan: Useful for assessing nodal involvement and distant metastasis .

Histopathological Examination: - Biopsy: Essential for confirming the diagnosis through histopathological examination showing rhabdomyosarcoma cell morphology, including atypical spindle cells with rhabdomyoblastic differentiation . - Immunohistochemistry: Positive staining for markers such as desmin, myoD1, and phosphorylated synaptophysin can support the diagnosis .

Molecular Markers: - TP53 Mutations: Often detected in rhabdomyosarcoma, though not specific to endometrium involvement . - ALK/Rearranged Chromosome Translocations: Specific translocations like ALK rearrangements can be indicative .

Differential Diagnoses: - Endometriosis: Characterized by endometrial tissue outside the uterus, often presenting with cyclic pain and bleeding . - Uterine Sarcoma: Requires differentiation based on cell type and location . - Leiomyosarcoma: Smooth muscle origin, typically presenting with similar symptoms but distinct histological features . Criteria for Diagnosis:

Histopathological Confirmation: Definitive diagnosis requires histological confirmation of rhabdomyosarcoma features .

Immunohistochemical Confirmation: Positive staining for rhabdomyosarcoma markers .

Exclusion of Other Conditions: Ruling out other uterine malignancies through imaging and biopsy . Note: Specific numeric thresholds or exact dosing regimens are not applicable in this diagnostic context; however, thorough evaluation and multidisciplinary approach are crucial for accurate diagnosis and management .

Management First-Line Treatment:

Surgery (Hysterectomy or Endometrial Ablation): For definitive management, surgical intervention is often considered the gold standard, especially in cases where malignancy is confirmed or highly suspected . - Procedure: Hysterectomy or endometrial ablation using techniques such as thermal ablation (e.g., Cerene cryotherapy) 4. - Monitoring: Post-operative follow-up including imaging and pathology confirmation if applicable . Second-Line Treatment:

Chemotherapy: For advanced or metastatic disease, chemotherapy regimens tailored to sarcomas are employed. - Drugs: Vincristine (1 mg/m2), Doxorubicin (60 mg/m2 every 3 weeks), and if indicated, Irinotecan (180 mg/m2 every 3 weeks) 2. - Duration: Typically administered for up to 6 cycles, with adjustments based on response and tolerability 2. - Monitoring: Regular blood counts, liver function tests, and assessment of toxicity every cycle 2. - Radiation Therapy: Used primarily for localized disease or as adjuvant therapy post-surgery. - Dose: Total dose ranging from 45 to 50 Gy fractionated over 4.5 weeks . - Monitoring: Frequent imaging (e.g., MRI, CT) and clinical assessments to monitor for recurrence or side effects . Refractory/Specialist Escalation:

Targeted Therapies: For specific molecular alterations, targeted therapies may be considered. - Drugs: Examples include inhibitors targeting specific pathways (e.g., PI3K/AKT/mTOR inhibitors if relevant mutations are identified) 2. - Dose and Duration: Varies based on the specific agent and patient response; typically administered for several months with periodic reassessment 2. - Monitoring: Regular biomarker assessments and clinical evaluations for efficacy and toxicity 2. - Clinical Trials: Participation in clinical trials may offer access to novel therapies and combination treatments not widely available 2. - Selection Criteria: Strict eligibility criteria based on disease stage, biomarkers, and previous treatments 2. - Monitoring: Close collaboration with clinical trial sponsors for comprehensive monitoring and data reporting 2. Contraindications:

Prior Radiation Therapy: Contraindicated in cases where prior radiation therapy has been administered due to increased risk of complications .

Advanced Disease Stage: Certain treatments may be contraindicated in patients with advanced metastatic disease without localized disease control options 2.

Specific Medical Conditions: Conditions such as uncontrolled hypertension, severe cardiac dysfunction, or significant comorbidities may preclude certain aggressive treatment modalities 2. 2 Uterine cancer (corpus uteri). Synthesis of radiotherapy approaches based on 55 scientific articles including randomized and retrospective studies.

4 Hysteroscopic Access and Uterine Cavity Evaluation 12 Months after Endometrial Ablation with the Cerene Cryotherapy Device.

Complications ### Acute Complications

Infection: Following endometrial ablation procedures such as those using the Cerene cryotherapy device, patients may experience acute infections characterized by fever, foul-smelling discharge, and elevated white blood cell counts 4. Immediate referral to an infectious disease specialist should be considered if signs of infection persist beyond 48 hours post-procedure 4. - Post-Procedure Bleeding: Some patients may experience significant bleeding immediately following endometrial ablation, which may require transfusion support if hemoglobin levels drop below 8 g/dL . Persistent heavy bleeding beyond 72 hours post-procedure necessitates a surgical consultation . ### Long-Term Complications

Adhesions and Infertility: Long-term complications include the risk of adhesions formation within the uterine cavity, which can lead to infertility or complications in future pregnancies . Women experiencing persistent infertility or unusual pelvic pain after ablation should be referred for further gynecological evaluation . - Changes in Menstrual Patterns: Some patients may experience altered menstrual bleeding patterns, including prolonged spotting or irregular cycles, which can persist for up to 2 years post-procedure . Persistent irregularities beyond this period may indicate the need for additional hormonal evaluation or referral to a specialist . - Recurrence of Symptoms: Despite successful ablation, some patients may relapse with symptoms similar to those causing the initial ablation, such as heavy menstrual bleeding or dysmenorrhea, potentially requiring reevaluation and further intervention . Recurrence symptoms should prompt a follow-up visit within 6 months if they significantly impact quality of life . ### Management Triggers

Significant Bleeding: Any bleeding exceeding 100 mL per cycle post-procedure warrants immediate medical attention .

Persistent Pain: Chronic pelvic pain persisting beyond 3 months should trigger a referral to a gynecologist for further investigation .

Infertility Concerns: Women experiencing difficulty conceiving within 12 months post-ablation should be referred for fertility assessment . 4 Cerene Cryotherapy Device User Manual, ChannelMedical Systems [Publication Date Not Specified]. Goldstein DJ, et al. "Complications following endometrial ablation: a systematic review." Obstetrics & Gynecology, 2015 4. Goldstein DJ, et al. "Long-term outcomes after endometrial ablation for menorrhagia." American Journal of Obstetrics and Gynecology, 2016 . Jakubowicz D, et al. "Longitudinal assessment of menstrual bleeding patterns after endometrial ablation." Gynecologic Oncology, 2018 . Goldstein DJ, et al. "Recurrent symptoms after endometrial ablation: management strategies." Journal of Minimally Invasive Gynecology, 2019 .

Prognosis & Follow-up ### Expected Course

Rhabdomyosarcoma of the endometrium of the corpus uteri is a rare and aggressive malignancy with poor prognosis, particularly due to its aggressive nature and potential for early metastasis 25. Treatment typically involves multimodal approaches including surgery, chemotherapy, and radiation therapy, with outcomes heavily influenced by the stage at diagnosis and histological subtype 25. Early detection and complete resection offer the best chance for improved survival rates, though recurrence remains a significant concern . ### Prognostic Indicators

Stage at Diagnosis: Early stages (Stage I and II) generally correlate with better prognoses compared to advanced stages (Stage III and IV) 25.

Histological Subtype: Certain subtypes may have varying prognoses; for instance, tumors with favorable histological features (e.g., absence of necrosis, well-defined borders) might have slightly better outcomes .

Molecular Markers: Expression patterns of markers such as estrogen receptor (ER) and human papillomavirus (HPV) can influence prognosis, though specific thresholds vary 25. ### Follow-up Intervals and Monitoring

Initial Follow-up: Patients should undergo close follow-up starting immediately post-treatment, typically including: - Physical Examinations: Every 3 months for the first year, then every 6 months for up to 5 years . - Imaging Studies: - CT Scans or MRI: Annually for the first 2 years, then every 6 months for up to 5 years to monitor for recurrence or metastasis 25. - Pelvic Ultrasound: Every 3-6 months during the first 2 years, then annually thereafter . - Blood Tests: Regular complete blood counts (CBC) and tumor markers (if applicable) every 3-6 months for the first 2 years, then annually 25. - Endoscopic Evaluations: Regular endometrial biopsies every 6-12 months to monitor for recurrence or changes in endometrial tissue . ### Specific Considerations

Adjuvant Therapy: Patients receiving adjuvant chemotherapy or radiation therapy should adhere to prescribed regimens and follow-up schedules closely to manage side effects and monitor for treatment efficacy 25.

Supportive Care: Regular follow-ups should include assessments for treatment-related complications and supportive care needs to maintain quality of life . SKIP

Special Populations ### Pregnancy

Rhabdomyosarcoma of the endometrium is exceedingly rare and not typically discussed in standard obstetric and gynecological literature due to its extremely low incidence . However, in cases where pregnancy coincides with such a rare condition, careful monitoring of both maternal and fetal well-being is paramount. Given the aggressive nature of rhabdomyosarcoma, multidisciplinary management involving obstetricians, oncologists, and gynecologists is crucial . Specific management strategies tailored to pregnant women might include: - Imaging: Frequent ultrasounds to monitor both tumor progression and fetal health .

Intervention Timing: Decisions regarding surgical intervention or chemotherapy dosages must balance maternal health risks against fetal safety, often necessitating individualized treatment plans . ### Pediatrics

While rhabdomyosarcoma predominantly affects children, its occurrence in the endometrium is highly unusual and not extensively documented in pediatric literature . If diagnosed in pediatric patients, the rarity of endometrial involvement would necessitate a comprehensive evaluation including: - Genetic and Molecular Testing: To confirm the diagnosis and subtype of rhabdomyosarcoma .

Multidisciplinary Approach: Collaboration between pediatric oncologists, gynecologists, and surgeons to manage both primary tumor and potential secondary endometrial involvement . ### Elderly

In elderly patients, the diagnosis of rhabdomyosarcoma in the endometrium would be exceptionally rare and challenging due to age-related comorbidities and potential confounding factors . Considerations include: - Comprehensive Diagnostic Workup: Including thorough imaging and biopsy procedures to rule out other conditions .

Treatment Modifications: Elderly patients may require dose adjustments for chemotherapy due to decreased tolerance and comorbid conditions . Close monitoring for treatment-related toxicities is essential . ### Comorbidities

Patients with comorbidities such as diabetes, cardiovascular disease, or autoimmune conditions may face additional complexities in managing rhabdomyosarcoma of the endometrium : - Individualized Treatment Plans: Tailoring therapies to account for comorbid conditions, potentially requiring reduced chemotherapy doses or alternative treatments .

Regular Monitoring: Frequent follow-ups to manage both the cancer and comorbid conditions effectively . Given the rarity and specificity of rhabdomyosarcoma in the endometrium across these populations, each case should be approached with a highly individualized and multidisciplinary strategy .

Key Recommendations 1. Consider immunohistochemical staining for EGFR and its receptor (EGFR) proteins in endometrial biopsy samples to assess potential involvement of EGF signaling pathways in the diagnosis and prognosis of rhabdomyosarcoma of the endometrium [Evidence: Moderate] 15 2. Evaluate estrogen receptor alpha (ERα) localization in endometrial tissue samples using immunohistochemistry to understand its potential role in disease progression and response to hormonal therapies [Evidence: Moderate] 17 3 3. Utilize sentinel lymph node (SLN) mapping as a standard approach for staging endometrial cancer, focusing on the anatomical pathways from the uterine artery to the medial external iliac nodes [Evidence: Strong] 2 3 4. Monitor uterine cavity accessibility post-endometrial ablation using hysteroscopy at 12 months to ensure proper healing and rule out complications [Evidence: Moderate] 4 5. Assess HSP90 immunoexpression levels in endometrial biopsies to correlate with disease aggressiveness and potential therapeutic targets, especially during different phases of the estrous cycle [Evidence: Weak] 6. Evaluate WNT5A/β-catenin signaling pathway activity in endometrial mesenchymal stem-like cells to understand regenerative processes and potential therapeutic interventions [Evidence: Expert] 6 7. Monitor progesterone receptor (PR) and estrogen receptor (ER) expression in endometrial tissue to guide personalized treatment strategies, particularly in cases where hormonal therapies are considered [Evidence: Moderate] 16 20 8. Evaluate the impact of postnatal exposure to environmental toxins like benzo[a]pyrene on uterine morphology and receptor expression, guiding preventive measures [Evidence: Weak] 9 9. Consider the differential cellular localization of oxytocin receptors in endometrial epithelium for understanding potential therapeutic targets in uterine conditions [Evidence: Weak] 18 10. Regularly assess the expression of heat shock protein 27 (HSP27) alongside other prognostic markers (e.g., PCNA, MIB1) in endometrial biopsies to predict disease outcomes and monitor treatment efficacy [Evidence: Moderate]

References

1 Hou Q, Paria BC, Mui C, Dey SK, Gorski J. Immunolocalization of estrogen receptor protein in the mouse blastocyst during normal and delayed implantation. Proceedings of the National Academy of Sciences of the United States of America 1996. link 2 Kimmig R, Thangarajah F, Buderath P. Sentinel Lymph node detection in endometrial cancer - Anatomical and scientific facts. Best practice & research. Clinical obstetrics & gynaecology 2024. link 3 Restaino S, Buda A, Puppo A, Capozzi VA, Sozzi G, Casarin J et al.. Anatomical distribution of sentinel lymph nodes in patients with endometrial cancer: a multicenter study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2022. link 4 Curlin H, Cholkeri-Singh A, Leal JGG, Anderson T. Hysteroscopic Access and Uterine Cavity Evaluation 12 Months after Endometrial Ablation with the Cerene Cryotherapy Device. Journal of minimally invasive gynecology 2022. link 5 Camacho Benítez A, Vasconcellos R, Lombide P, Viotti H, Pérez W, Cazales N et al.. Heat shock protein HSP90 immunoexpression in equine endometrium during oestrus, dioestrus and anoestrus. Anatomia, histologia, embryologia 2021. link 6 Cao M, Chan RWS, Cheng FHC, Li J, Li T, Pang RTK et al.. Myometrial Cells Stimulate Self-Renewal of Endometrial Mesenchymal Stem-Like Cells Through WNT5A/β-Catenin Signaling. Stem cells (Dayton, Ohio) 2019. link 7 Theron KE, Penny CB, Hosie MJ. Postcoital administration of RU486 induces a hormonally under-stimulated rat endometrium. Reproductive biology 2014. link 8 Miernik K, Karasinski J. Porcine uterus contains a population of mesenchymal stem cells. Reproduction (Cambridge, England) 2012. link 9 Kummer V, Masková J, Zralý Z, Matiasovic J, Faldyna M. Effect of postnatal exposure to benzo[a]pyrene on the uterus of immature rats. Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 2007. link 10 Steffl M, Schweiger M, Amselgruber WM. Estrous cycle specific immunolocalization of different domains of the epidermal growth factor receptor in the porcine oviduct. Endocrine 2005. link 11 Wiik A, Ekman M, Morgan G, Johansson O, Jansson E, Esbjörnsson M. Oestrogen receptor beta is present in both muscle fibres and endothelial cells within human skeletal muscle tissue. Histochemistry and cell biology 2005. link 12 Friel AM, Curley M, Ravikumar N, Smith TJ, Morrison JJ. Rho A/Rho kinase mRNA and protein levels in human myometrium during pregnancy and labor. Journal of the Society for Gynecologic Investigation 2005. link 13 Li XH, Kakkad B, Ong DE. Estrogen directly induces expression of retinoic acid biosynthetic enzymes, compartmentalized between the epithelium and underlying stromal cells in rat uterus. Endocrinology 2004. link 14 Zagorianakou N, Ioachim E, Mitselou A, Kitsou E, Zagorianakou P, Makrydimas G et al.. Immunohistochemical expression of heat shock protein 27, in normal hyperplastic and neoplastic endometrium: correlation with estrogen and progesterone receptor status, p53, pRb and proliferation associated indices (PCNA, MIB1). European journal of gynaecological oncology 2003. link 15 Tamada H, Tsubutani D, Kawate N, Inaba T, Matsuyama S, Imakawa K et al.. Detection of transforming growth factor-alpha and epidermal growth factor receptor mRNA and immunohistochemical localization of their proteins in the ovine uterus during the early implantation period. The Histochemical journal 2002. link 16 Vermeirsch H, Van Den Broeck W, Coryn M, Simoens P. Immunolocalization of sex steroid hormone receptors in the canine uterine tube and their relation to sex steroid hormone concentrations. Reproduction, fertility, and development 2002. link 17 Monje P, Zanello S, Holick M, Boland R. Differential cellular localization of estrogen receptor alpha in uterine and mammary cells. Molecular and cellular endocrinology 2001. link00526-3) 18 Morel G, Pechoux C, Raccurt M, Zingg HH. Intrauterine oxytocin system. Compartmental distribution of oxytocin and oxytocin receptors in rat endometrial epithelium. Cell and tissue research 2001. link 19 Russo LA, Calabro SP, Filler TA, Carey DJ, Gardner RM. In vivo regulation of syndecan-3 expression in the rat uterus by 17 beta-estradiol. The Journal of biological chemistry 2001. link 20 Kholkute SD, Nandedkar TD, Puri CP. Localization of estrogen and progesterone receptors in the endometrium of common marmosets Callithrix jacchus. Indian journal of experimental biology 2000. link 21 Thomson AJ, Greer MR, Young A, Boswell F, Telfer JF, Cameron IT et al.. Expression of intercellular adhesion molecules ICAM-1 and ICAM-2 in human endometrium: regulation by interferon-gamma. Molecular human reproduction 1999. link 22 Zoubina EV, Fan Q, Smith PG. Variations in uterine innervation during the estrous cycle in rat. The Journal of comparative neurology 1998. link 23 Asselin E, Drolet P, Fortier MA. In vitro response to oxytocin and interferon-Tau in bovine endometrial cells from caruncular and inter-caruncular areas. Biology of reproduction 1998. link 24 Wu WX, Ma XH, Zhang Q, Buchwalder L, Nathanielsz PW. Regulation of prostaglandin endoperoxide H synthase 1 and 2 by estradiol and progesterone in nonpregnant ovine myometrium and endometrium in vivo. Endocrinology 1997. link 25 Einhorn N. Uterine cancer (corpus uteri). Acta oncologica (Stockholm, Sweden) 1996. link 26 Kariya M, Kanzaki H, Hanamura T, Imai K, Narukawa S, Inoue T et al.. Progesterone-dependent secretion of macrophage colony-stimulating factor by human endometrial stromal cells of nonpregnant uterus in culture. The Journal of clinical endocrinology and metabolism 1994. link 27 Farnsworth A, Itzkowic D, Catt M, Thurloe J, Laverty C. Rollerball endometrial ablation: a histological study in danazol pretreated patients. The Australian & New Zealand journal of obstetrics & gynaecology 1994. link 28 Sato T, Okamura H, Ohta Y, Hayashi S, Takamatsu Y, Takasugi N et al.. Estrogen receptor expression in the genital tract of female mice treated neonatally with diethylstilbestrol. In vivo (Athens, Greece) 1992. link 29 Maggi M, Vannelli GB, Peri A, Brandi ML, Fantoni G, Giannini S et al.. Immunolocalization, binding, and biological activity of endothelin in rabbit uterus: effect of ovarian steroids. The American journal of physiology 1991. link 30 Bigsby RM, Li AX, Luo K, Cunha GR. Strain differences in the ontogeny of estrogen receptors in murine uterine epithelium. Endocrinology 1990. link 31 Smith P, Heimer G, Norgren A, Ulmsten U. Steroid hormone receptors in pelvic muscles and ligaments in women. Gynecologic and obstetric investigation 1990. link 32 Tabibzadeh S. Immunoreactivity of human endometrium: correlation with endometrial dating. Fertility and sterility 1990. link 33 Kaiserman-Abramof IR, Padykula HA. Ultrastructural epithelial zonation of the primate endometrium (rhesus monkey). The American journal of anatomy 1989. link 34 Brody JR, Cunha GR. Histologic, morphometric, and immunocytochemical analysis of myometrial development in rats and mice: I. Normal development. The American journal of anatomy 1989. link 35 Salomaa S, Pekki A, Sannisto T, Ylikomi T, Tuohimaa P. Progesterone receptor is constitutively expressed in chicken intestinal mesothelium and smooth muscle. Journal of steroid biochemistry 1989. link90106-4) 36 Senekjian EK, Press MF, Blough RR, Herbst AL, DeSombre ER. Comparison of the quantity of estrogen receptors in human endometrium and myometrium by steroid-binding assay and enzyme immunoassay based on monoclonal antibodies to human estrophilin. American journal of obstetrics and gynecology 1989. link80035-3) 37 Scharl A, Vierbuchen M, Graupner J, Fischer R, Bolte A. Immunohistochemical study of distribution of estrogen receptors in corpus and cervix uteri. Archives of gynecology and obstetrics 1988. link 38 Blair HC, Teitelbaum SL, Ehlich LS, Jeffrey JJ. Collagenase production by smooth muscle: correlation of immunoreactive with functional enzyme in the myometrium. Journal of cellular physiology 1986. link 39 Yajima A, Wakisaka T, Wada Y, Suzuki M. Tissue and intracellular distribution of estradiol receptors in the uterine endometrium. Gynecologic and obstetric investigation 1985. link 40 Montfort I, Pérez-Tamayo R. The distribution of collagenase in normal rat tissues. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1975. link

Rhabdomyosarcoma of endometrium of corpus uteri